Dynavax Urges Stockholders To Re-Elect All Four Director Nominees Ahead Of June 11 Meeting

Dynavax Technologies is urging stockholders to re-elect its four board nominees at the June 11, 2025, annual meeting, countering activist investor Deep Track's proposal to replace them. Dynavax argues its nominees possess critical expertise for long-term growth and accuses Deep Track of prioritizing short-term gains. Proxy advisors ISS, Egan-Jones, and Glass Lewis support Dynavax's nominees, citing the company's strong performance, including a 203% five-year total return, and questioning Deep Track's motives and nominee qualifications.

Analysis

Dynavax Technologies (DVAX) is vigorously defending its current board composition against an activist challenge from Deep Track, urging shareholders to re-elect its four nominees at the upcoming Annual Meeting on June 11, 2025. The company asserts that its nominees possess critical expertise in biotech, vaccines, M&A, and financial strategy, essential for sustaining long-term growth, and characterizes Deep Track's proposal as a "strip-mining" strategy detrimental to sustainable value. This defensive stance is significantly bolstered by endorsements from independent proxy advisory firms ISS, Egan-Jones, and Glass Lewis, which support Dynavax's slate. These advisors have cited Deep Track's flawed arguments, misleading claims, and the questionable qualifications of its principal, while highlighting Dynavax's strong 203 percent five-year total return and the successful market performance of its key product, HEPLISAV-B. The situation underscores a pivotal moment for Dynavax's strategic continuity, with the current leadership emphasizing its successful repositioning and operational execution. The stock (DVAX) closed at $10.28, remaining stable in after-hours trading, indicating the market may be awaiting the vote's outcome.

Key Decisions for Investors

• Investors should consider the strong endorsements from proxy advisors ISS, Egan-Jones, and Glass Lewis for Dynavax's current board nominees when casting their votes for the June 11, 2025, Annual Meeting.
• Given Dynavax's reported 203% five-year total return and the commercial success of HEPLISAV-B under the current leadership, supporting the incumbent board aligns with maintaining strategic continuity and potentially preserving long-term value creation.
• Monitor the outcome of the shareholder vote closely, as a successful defense against Deep Track would likely reinforce the current strategy, whereas an unexpected board change could introduce uncertainty and potentially trigger a strategic review.